Eleni Daniel
University of Sheffield
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eleni Daniel.
European Journal of Endocrinology | 2015
Eleni Daniel; John Newell-Price
Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushings syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors in the management of CS, including older agents (KTZ, metyrapone, etomidate and mitotane) and those currently under development (LCI699, non-racemic KTZ), and offer a practical approach for their use in clinical practice.
Pituitary | 2015
Eleni Daniel; John Newell-Price
Diagnosis of Cushings disease frequently remains a challenge. In this review we critically appraise the clinical features, biochemical tests, and imaging modalities used for this purpose. We outline recommendations for approaches to clinical investigation, with a particular focus on developments made within the last two years.
Blood | 2016
Robert C. Jones; Kate E. McDonald; Joseph A. Willson; Bart Ghesquière; David Sammut; Eleni Daniel; Alison J. Harris; Amy Lewis; A. A. Roger Thompson; Rebecca S. Dickinson; Tracie Plant; Fiona Murphy; Pranvera Sadiku; Brian Keevil; Peter Carmeliet; Moira K. B. Whyte; John Newell-Price; Sarah R. Walmsley
To the editor: Neutrophils are unusual in their reliance on glycolysis to maintain their energy requirements[1][1] despite the presence of mitochondria and tricarboxylic acid (TCA) cycle intermediaries.[2][2] This metabolic adaptation is thought in part to underpin their survival and antimicrobial
F1000Research | 2017
Eleni Daniel; John Newell-Price
Cushing’s disease is a rare disease with a characteristic phenotype due to significant hypercortisolism driven by over-secretion of adrenocorticotropic hormone and to high morbidity and mortality if untreated. It is caused by a corticotroph adenoma of the pituitary, but the exact mechanisms leading to tumorigenesis are not clear. Recent advances in molecular biology such as the discovery of somatic mutations of the ubiquitin-specific peptidase 8 ( USP8) gene allow new insights into the pathogenesis, which could be translated into exciting and much-needed therapeutic applications.
Clinical Endocrinology | 2017
Nayananjani Karunasena; Thang S. Han; Ashwini Mallappa; Meredith Elman; Deborah P. Merke; Richard Ross; Eleni Daniel
Hyperandrogenism in congenital adrenal hyperplasia (CAH) provides an in vivo model for exploring the effect of androgens on erythropoiesis in women. We investigated the association of androgens with haemoglobin (Hb) and haematocrit (Hct) in women with CAH.
European Journal of Endocrinology | 2016
Eleni Daniel; Robert C. Jones; Matthew Bull; John Newell-Price
BACKGROUND Patients with SDHx mutations need long-term radiological surveillance for the development of paragangliomas and phaeochromocytomas, but no longitudinal data exist. The aim of the study was to assess the performance of rapid-sequence non-contrast magnetic resonance imaging (MRI) in the long-term monitoring of patients with SDHx mutations. METHODS Retrospective study between 2005 and 2015 at a University Hospital and regional endocrine genetics referral centre. Clinical and imaging data of 47 patients with SDHx mutations (SDHB (36), SDHC (6) and SDHD (5)) who had surveillance for detection of paragangliomas by rapid-sequence non-contrast MRI (base of skull to pubic symphysis) were collected. RESULTS Twelve index cases (nine SDHB, one SDHC and two SDHD) and 35 mutation-positive relatives were monitored for a mean of 6.4 years (range 3.1-10.0 years). Mean age at the end of the study: SDHB 46.9 ± 17.6 years; SDHC 42.3 ± 24.4 years; SDHD 54.9 ± 10.6 years. On excluding imaging at initial diagnosis of index cases, 42 patients underwent 116 rapid-sequence MRI scans: 83 scans were negative and 31 scans were positive for sPGL/HNPGL in 13 patients. Most patients had multiple scans (n = number of patients (number of rapid-sequence MRI scans during screening)): n = 9 (2), n = 20 (3), n = 6 (4), n = 1 (6). Nine patients (three index) were diagnosed with new paragangliomas during surveillance and non-operated tumour size was monitored in nine patients. There were two false-positive scans (1.6%). Scans were repeated every 27 ± 9 months. CONCLUSIONS Biannual rapid-sequence non-contrast MRI is effective to monitor patients with SDHx mutations for detection of new tumours and monitoring of known tumours.
Clinical Endocrinology | 2018
Eleni Daniel; Martin Whitaker; Brian Keevil; J. K. H. Wales; Richard Ross
Hydrocortisone via nasogastric (NG) tube is used in sick children with adrenal insufficiency; however, there is no licensed formulation for NG administration.
Medicine | 2001
Eleni Daniel; John Newell-Price
The Journal of Clinical Endocrinology and Metabolism | 2015
Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J. Cuthbertson; Christina Daousi; Surya Panicker Rajeev; Julian R. E. Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley B. Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huguet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil E. Hill; Aled Rees; Andrew Lansdown; Peter J Trainer; Anna-Elisabeth H Minder; John Newell-Price
Endocrine Abstracts | 2014
Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J Cuthbertson; Christina Daousi; Surya Panicker Rajeev; Julian R. E. Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huquet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil E. Hill; Aled Rees; Peter Trainer; Andrew Lansdown; Anna-Elisabeth H Minder; John Newell-Price